Predicting lung damage from radiation and immunotherapy
Part of Cancer, Injuries & trauma, Lungs & breathing clinical trials.
This study looks at whether certain biological markers can predict lung injury in people receiving both immunotherapy and radiation for lung cancer. The goal is to identify who might be at higher risk, so treatment can be tailored to reduce harm.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a life expectancy of at least 6 months.
- Your performance status must be 0 or 1, meaning you are fully active or only restricted in physically strenuous activity.
- You must have had a baseline chest CT scan before starting immunotherapy.
- You must have received at least 2 cycles of PD-1 inhibitor therapy (alone or combined) within the past 6 months.
- You must have received thoracic radiation of at least 30 Gy, and you should not have taken antibiotics within 1 week before starting that radiation.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding radiation to the liver can make immunotherapy and chemotherapy work better for people with lung cancer that has spread to the liver. It's for patients who have already tried standard treatments, including immunotherapy, and need new options.
This trial tests adding targeted radiation before standard immunotherapy and chemotherapy for people with stage 2-3 non-small cell lung cancer that can be surgically removed. The goal is to see if the radiation helps shrink the tumor more before surgery.
This study is looking at how the immune system responds to immunotherapy in people with advanced non-small cell lung cancer. By collecting sputum (mucus from your lungs) and blood samples, researchers hope to find clues that could help predict treatment outcomes.
This study looks at ways to predict who will develop radiation pneumonitis (lung inflammation after radiation) and how outcomes vary. It may help doctors better watch and treat lung side effects after lung cancer radiation.
This study monitors how the heart and lungs respond to radiation therapy combined with immunotherapy for locally advanced lung cancer. It aims to learn how well patients tolerate treatment and to detect early signs of side effects.
This study looks for signs in the blood that can tell if a lung cancer patient is developing a side effect called pneumonitis (lung inflammation) from checkpoint inhibitor treatment. It may help doctors catch and treat this side effect early.
Hear when a new Lung Cancer (NSCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.